CXCL8 and neoplasm: Engineering CAR T-cells to coexpress chemokine receptors, such as CXCR1 or CXCR2 for IL-8-secreting ovarian or pancreatic tumors, may be an additional strategy to direct cells to the tumor and mitigate on-target/off-tumor toxicity in other tissues [203].